New and emerging disease modifying therapies for multiple sclerosis

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Related B cell clones populate the meninges and parenchyma of patients with multiple sclerosis

(2011) Laura Lovato et al.   BRAIN

Glatiramer Acetate Treatment of Multiple Sclerosis: An Immunological Perspective

(2011) M. K. Racke et al.   JOURNAL OF IMMUNOLOGY

Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment

(2011) Kerstin Hellwig et al.   Multiple Sclerosis Journal

A role for interleukin-2 trans-presentation in dendritic cell–mediated T cell activation in humans, as revealed by daclizumab therapy

(2011) Simone C Wuest et al.   NATURE MEDICINE

Interruption of natalizumab therapy for multiple sclerosis: What are the risks?

(2011) R. T. Naismith et al.   NEUROLOGY

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS

(2011) M. C. Kowarik et al.   NEUROLOGY

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

(2011) P. Vermersch et al.   NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

The Nrf2-ARE Pathway

(2010) Jeffrey A. Johnson et al.   Annals of the New York Academy of Sciences

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study

(2010) Mikkel Østergaard et al.   ARTHRITIS AND RHEUMATISM

Oral Therapies for Multiple Sclerosis

(2010) Ralf Gold   CNS DRUGS

Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes

(2010) Heidi J. Salminen et al.   JOURNAL OF NEUROLOGY

PML risk and natalizumab: more questions than answers

(2010) Richard M Ransohoff   LANCET NEUROLOGY

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

(2010) Daniel Wynn et al.   LANCET NEUROLOGY

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial

(2010) Raju Kapoor et al.   LANCET NEUROLOGY

Ofatumumab

(2010) Bodi Zhang   mAbs

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

(2010) G. Comi et al.   Multiple Sclerosis Journal

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

PML problems loom for Rituxan

(2010) Malorye Allison   NATURE BIOTECHNOLOGY

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

(2010) Volker Brinkmann et al.   NATURE REVIEWS DRUG DISCOVERY

CRITICAL VASOSPASM DURING FINGOLIMOD (FTY720) TREATMENT IN A PATIENT WITH MULTIPLE SCLEROSIS

(2010) A. Schwarz et al.   NEUROLOGY

Cross-sectional study assessing long-term safety of interferon- -1b for relapsing-remitting MS

(2010) A. T. Reder et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dimethylfumarate inhibits NF-κB function at multiple levels to limit airway smooth muscle cell cytokine secretion

(2009) P. Seidel et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies

(2009) Eugene O. Major   Annual Review of Medicine

Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis

(2009) Massimiliano Calabrese et al.   ARCHIVES OF NEUROLOGY

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

(2009) K. R. Carson et al.   BLOOD

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta

(2009) Giancarlo Comi   CLINICAL THERAPEUTICS

Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis

(2009) D. Moharregh-Khiabani et al.   Current Neuropharmacology

Benefit-Risk Assessment of Leflunomide

(2009) Nicola Alcorn et al.   DRUG SAFETY

Ocrelizumab: a step forward in the evolution of B-cell therapy

(2009) Fariha Kausar et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis – A retrospective study (FUTURE)

(2009) Kristian Reich et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis

(2009) Sara A. J. Thompson et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX

(2009) A. W. Pawluczkowycz et al.   JOURNAL OF IMMUNOLOGY

Cellular approaches to central nervous system remyelination stimulation: thyroid hormone to promote myelin repair via endogenous stem and precursor cells

(2009) Laura Calzà et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Association between MRI parameters and the MS severity scale: a 12 year follow-up study

(2009) A Minneboo et al.   Multiple Sclerosis Journal

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

(2009) G. Comi et al.   Multiple Sclerosis Journal

Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study

(2009) C Weber-Schoendorfer et al.   Multiple Sclerosis Journal

HEMORRHAGING FOCAL ENCEPHALITIS UNDER FINGOLIMOD (FTY720) TREATMENT: A CASE REPORT

(2009) F. Leypoldt et al.   NEUROLOGY

PML-IRIS in patients with HIV infection: Clinical manifestations and treatment with steroids

(2009) K. Tan et al.   NEUROLOGY

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

(2009) B. O. Khatri et al.   NEUROLOGY

Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study

(2009) P. O'Connor et al.   NEUROLOGY

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis

(2009) Monica A. Rojas et al.   Therapeutic Advances in Neurological Disorders

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Inflammatory demyelination induces axonal injury and retinal ganglion cell apoptosis in experimental optic neuritis

(2008) Kenneth S. Shindler et al.   EXPERIMENTAL EYE RESEARCH

Nrf2-regulated glutathione recycling independent of biosynthesis is critical for cell survival during oxidative stress

(2008) C.J. Harvey et al.   FREE RADICAL BIOLOGY AND MEDICINE

Central nervous system-directed effects of FTY720 (fingolimod)

(2008) Veronique E. Miron et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) G Comi et al.   LANCET

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Anti–Glomerular Basement Membrane Disease after Alemtuzumab

(2008) Menna R. Clatworthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Optical coherence tomography: a window into the mechanisms of multiple sclerosis

(2008) Elliot M Frohman et al.   Nature clinical practice. Neurology

Nrf2 signaling: An adaptive response pathway for protection against environmental toxic insults

(2007) W OSBURN et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH